Technical Analysis for CYCCP - Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Grade Last Price % Change Price Change
grade F 4.8228 -1.58% -0.08
CYCCP closed down 1.58 percent on Tuesday, September 17, 2019, on 30 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CYCCP trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Fell Below 20 DMA Bearish -1.58%
Narrow Range Bar Range Contraction -1.58%
Crossed Above 20 DMA Bullish -6.09%
MACD Bullish Signal Line Cross Bullish -6.09%
Narrow Range Bar Range Contraction -6.09%
Gapped Up Strength -6.09%
MACD Bearish Signal Line Cross Bearish -1.17%

Older signals for CYCCP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Serious Diseases Autoimmune And Inflammatory Diseases Cyclacel Treatment Of Autoimmune And Inflammatory Diseases Dna Synthesis PLK1 Cdk Inhibitor Cell Cycle Cell Cycle Checkpoint Cyclin Dependent Kinase Cyclin Dependent Kinase 2 E Human Cancers M Checkpoint Sapacitabine Seliciclib
Is CYCCP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.75
52 Week Low 4.46
Average Volume 1,008
200-Day Moving Average 5.9691
50-Day Moving Average 5.2128
20-Day Moving Average 5.0136
10-Day Moving Average 4.9015
Average True Range 0.376
ADX 9.92
+DI 35.5984
-DI 37.1292
Chandelier Exit (Long, 3 ATRs ) 4.732
Chandelier Exit (Short, 3 ATRs ) 5.698
Upper Bollinger Band 5.6347
Lower Bollinger Band 4.3925
Percent B (%b) 0.35
BandWidth 24.776608
MACD Line -0.0762
MACD Signal Line -0.0727
MACD Histogram -0.0035
Fundamentals Value
Market Cap 54.98 Million
Num Shares 11.4 Million
EPS -2.37
Price-to-Earnings (P/E) Ratio -2.04
Price-to-Sales 165.09
Price-to-Book 2.66
PEG Ratio 0.00
Dividend 0.60
Dividend Yield 12.44%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.94
Resistance 3 (R3) 4.95 4.93 4.92
Resistance 2 (R2) 4.93 4.90 4.92 4.91
Resistance 1 (R1) 4.87 4.88 4.86 4.86 4.91
Pivot Point 4.85 4.85 4.84 4.84 4.85
Support 1 (S1) 4.80 4.82 4.78 4.78 4.74
Support 2 (S2) 4.77 4.80 4.76 4.73
Support 3 (S3) 4.72 4.77 4.73
Support 4 (S4) 4.71